PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Jian Yue

Chinese Academy of Medical Sciences & Peking Union Medical College

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 11, 2026 · JOURNAL ARTICLE

Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study

Holistic Integrative Oncology

Real-world retrospective cohort with substantial sample size and mature follow-up reporting clinically relevant survival outcomes, but lacks randomized control and prospective design needed for practice-changing or strong evidence.

PromisingNanoparticle-based Drug Delivery Lili Zhang Jin Zhang

Reported

Sample size526

Median age53.0 years

Median follow-up856 days

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support